TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35229548
Drug: Pomegranate peel
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate peel extract (PoPEx) 250 mg twice daily
Study: 35229548
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily
Study: 33616555
Drug: 0.85% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85% saline solution for 20 minutes (control)
Study: 33616555
Drug: Brush immersion
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush immersion in solutions (SH, Efferdent, RC)
Study: 34156129
Drug: Milk thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk thistle meal (30 g/kg)
Study: 34156129
Drug: Poultry oil
Normalized name: Cocci-Cure P for Poultry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poultry oil and milk thistle meal (30 g/kg)
Study: 34289823
Drug: Nintedanib 50-150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 50-150 mg BID
Study: 36247420
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg a day on top of antidiabetic treatment)
Study: 36247420
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg a day)
Study: 32306085
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of balneotherapy (daily whirlpool baths, hydrokinesitherapy sessions, knee shower/massages)
Study: 32306085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual analgesia medication only)
Study: 35333744
Drug: Alfaxalone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (5 mg/kg)
Study: 35333744
Drug: Alfaxalone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (5 mg/kg) and midazolam (0.5 mg/kg)
Study: 37315099
Drug: Intolerance-of-uncertainty therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intolerance-of-uncertainty therapy (IUT)
Study: 34134024
Drug: ReVeRe.D (iPad-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReVeRe.D (iPad-administered cognitive test battery)
Study: 34134024
Drug: examiner-administered tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: examiner-administered tests
Study: 33081705
Drug: Telehealth Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Study: 34550483
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles
Study: 34550483
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin combination
Study: 32319955
Drug: Paper-and-pencil followed
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil followed by tablet app
Study: 32319955
Drug: Tablet only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet only
Study: 35139812
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Ranibizumab (IVR) 1 or 3 days before vitrectomy
Study: 35139812
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Ranibizumab (IVR) 3 days before vitrectomy
Study: 35139812
Drug: Sham subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham subconjunctival injection 3 days before surgery
Study: 35733997
Drug: MET (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (metformin therapy)
Study: 32503663
Drug: Inhaled sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled sargramostim 125 μg twice daily for 5 days
Study: 35665035
Drug: Functional acupuncture
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional acupuncture (FA) and routine rehabilitation treatment
Study: 35665035
Drug: Traditional acupuncture
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional acupuncture (TA) and routine rehabilitation treatment
Study: 33397663
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention guided by the HEARTS technical package, including training of NCD service providers, provision of essential equipment/supporting materials, and monthly monitoring and feedback.
Study: 33093013
Drug: Myofunctional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional therapy app
Study: 35148732
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (HYAcorp Endogel)
Study: 35148732
Drug: Ovarian suspension
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian suspension
Study: 34134794
Drug: L-citrulline (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (12 g)
Study: 32711655
Drug: Gold nanomaterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold nanomaterial (GNP) contrast agent used in medical imaging tests
Study: 35997582
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (qHPV)
Study: 37356077
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg (single dose)
Study: 33278016
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Study: 33278016
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Study: 33587431
Drug: Preemptive antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive antiviral therapy (PET)
Study: 36124667
Drug: Monte Carlo
Normalized name: Carbo animalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monte Carlo g-computation
Study: 36124667
Drug: ICE g-computation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE g-computation
Study: 33217600
Drug: Thrombin gel
Normalized name: THROMBIN GELATIN FOAM #10 TOP PAD
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin gel matrix (TGM), Floseal, applied at 5 mL to the pelvic sidewalls after lymphadenectomy
Study: 32005780
Drug: Peer counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer counselling intervention with trained peer counsellors providing weekly contact and face-to-face meetings every fortnight.
Study: 35608802
Drug: Primary-site locoregional
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary-site locoregional therapy (PSLT)
Study: 32211883
Drug: Integrase inhibitor
Normalized name: Integrase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase inhibitor exposure (ritonavir-boosted darunavir + raltegravir)
Study: 35613820
Drug: Embedded physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embedded physical therapy intervention
Study: 32434234
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of topical and intravenous tranexamic acid (TXA)
Study: 32434234
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) alone
Study: 32434234
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of IA and IV TXA
Study: 32434234
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of topical and IV TXA
Study: 33407156
Drug: Dexmedetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion)
Study: 33407156
Drug: Lidocaine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion)
Study: 33407156
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus Dexmedetomidine (combination of both interventions)
Study: 34028496
Drug: Antiseizure medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medication (ASM) discontinued at discharge
Study: 34028496
Drug: Antiseizure medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medication (ASM) maintained at discharge
Study: 34028496
Drug: Antiseizure medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medication (ASM) discontinued
Study: 34028496
Drug: Antiseizure medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medication (ASM) maintained
Study: 33225960
Drug: IFNβ-1a (44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ-1a (44 mcg, three times per week for 2 weeks)
Study: 35363631
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BFT)
Study: 32404343
Drug: Adalimumab taper
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab taper (every 3 weeks) for 36 weeks
Study: 32580032
Drug: lifestyle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: lifestyle plus metformin
Study: 35440464
Drug: sintilimab with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab with chemotherapy (cisplatin plus paclitaxel)
Study: 35440464
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with chemotherapy (cisplatin plus paclitaxel)
Study: 35440464
Drug: sintilimab with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab with chemotherapy (cisplatin plus 5‐fluorouracil)
Study: 35440464
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with chemotherapy (cisplatin plus 5‐fluorouracil)
Study: 33376173
Drug: Pharmacist-led medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacist-led medicines management
Study: 32996172
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy alone (control)
Study: 32400354
Drug: Multiyear mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiyear mass drug administration (MDA) with praziquantel, provided biannually and/or supplemented by additional interventions.
Study: 36307187
Drug: NHF 6
Normalized name: Nifuroxazide
DrugBank: Nifuroxazide (DB13855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHF 6 L/min, FiO2 1.0
Study: 36307187
Drug: NHF 0
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHF 0 L/min (control)
Study: 34618744
Drug: Structured neonatal
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured neonatal physical therapy program (SNP), 90 minutes/day, 6 days/week until discharge
Study: 33297831
Drug: Vinegar drink
Normalized name: Emergen-C Apple Cider Vinegar Drink Mix Powder for Solution (Apple)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinegar drink (two tablespoons vinegar in a cup of water; 3.6 g acetic acid)
Study: 33297831
Drug: Commercial vinegar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial vinegar pill (control, 0.045 g acetic acid)
Study: 38983921
Drug: Sevoflurane-based inhalation
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-based inhalation anesthesia
Study: 32424576
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in urologic therapy
Study: 32870434
Drug: Arthrocentesis using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis using Shepard's cannula and lactated Ringer's solution
Study: 32870434
Drug: Glucocorticosteroid (GCS)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroid (GCS) injection using 1 ml/40 mg methylprednisolone acetate
Study: 35594551
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m2)
Study: 33901450
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (before disc repositioning)
Study: 34989159
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/day) in addition to usual care
Study: 32066504
Drug: Amantadine sulphate
Normalized name: Amantadine sulphate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine sulphate (PK‐Merz®; twice 100 mg orally daily)
Study: 35505326
Drug: Calcium (600
Normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (600 mg) alone
Study: 35505326
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU per day) combined with Calcium (600 mg)
Study: 33272643
Drug: Controlled-release pregabalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release pregabalin (GLA5PR GLARS-NF1 tablets)
Study: 33272643
Drug: Immediate-release pregabalin
Normalized name: pregabalin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release pregabalin capsule
Study: 32500717
Drug: Acamprosate (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (two tablets of 333 mg/d, three times a day)
Study: 32500717
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets, three times a day)
Study: 36036644
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS combined with physical therapy
Study: 36036644
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS combined with physical therapy
Study: 36036644
Drug: Dual tDCS
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual tDCS combined with physical therapy
Study: 36036644
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with physical therapy
Study: 34096381
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education and counseling intervention (details on dosage and duration not specified)
Study: 34606332
Drug: Zoliflodacin 2
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin 2 g (therapeutic)
Study: 34606332
Drug: Zoliflodacin 4
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin 4 g (supratherapeutic)
Study: 34606332
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (positive comparator)
Study: 35007899
Drug: Peppermint essential
Normalized name: Nature's Truth Peppermint Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint essential oil inhalation (100% peppermint essential oil, 1 hour duration)
Study: 34052943
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conscious sedation (CS) with propofol and sufentanil (0.1 mg/kg)
Study: 34052943
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation (DS) with propofol and sufentanil (0.05 mg/kg)
Study: 32831908
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of Vitamin K2 + a calcinated magnesium placebo (n = 12)
Study: 32831908
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 + 100 μg vitamin K2 (n = 12)
Study: 36285519
Drug: Dalpiciclib 100
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 100 mg
Study: 36285519
Drug: Dalpiciclib 125
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 125 mg
Study: 36285519
Drug: Dalpiciclib 150
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib 150 mg
Study: 33710347
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with additional differential treatment component
Study: 33066869
Drug: Methylcobalamin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin (500 mcg/day)
Study: 33066869
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day) + Methylcobalamin (500 mcg/day)
Study: 33066869
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral anti-diabetic drugs
Study: 35533490
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy applied before deep breathing and coughing exercises
Study: 32479544
Drug: Lifestyle (LS)
Normalized name: bisoprolol fumarate Oral Tablet [Emcor LS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle (LS) programme with CBT, healthy diet, and physical therapy
Study: 33109859
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 μg/kg/h
Study: 33109859
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg/h
Study: 36362704
Drug: Proactive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive therapy (intermittent use of a very strong topical corticosteroid for 4 weeks)
Study: 36362704
Drug: Rank-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rank-down therapy (daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks)
Study: 36362704
Drug: Rank-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rank-down therapy
Study: 36362704
Drug: Proactive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive therapy
Study: 33017662
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (post-allo-HSCT)
Study: 36045468
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of essential oils and 0.12% chlorhexidine mouthwash
Study: 37494942
Drug: Bictegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg)
Study: 35483297
Drug: Sham AurPrs
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham AurPrs treatment
Study: 33875811
Drug: Stoss therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoss therapy (single high-dose oral vitamin D therapy) plus weekly/daily supplementation
Study: 32663945
Drug: Deceptive active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deceptive active placebo via intranasal application with expectancy-enhancing instructions
Study: 32303737
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAC) injections (10 mg/ml), with up to three injections administered over 12 weeks (initial injection, followed by two additional injections 6 weeks apart).
Study: 32303737
Drug: TAC injections
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC injections (10 mg/ml).
Study: 33298143
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg orally twice a day for 10 days
Study: 33298143
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G 2.4 M IU intramuscularly once
Study: 32389377
Drug: Fully guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully guided protocol with cylindrical guiding holes (12 implants)
Study: 32389377
Drug: Fully guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully guided protocol with C-shaped guiding holes (12 implants)
Study: 32389377
Drug: Partially guided
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially guided protocol with cylindrical guiding holes (12 implants)
Study: 32389377
Drug: Partially guided
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially guided protocol with C-shaped guiding holes (12 implants)
Study: 33211352
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% timolol maleate (TM) applied to one cheek
Study: 35268024
Drug: Gummy L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gummy L. plantarum Dad‐13 (108‐9 CFU/3 g) for 50 days
Study: 32798463
Drug: Delayed stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed stenting (after 24 to 48 hours with antithrombin therapy)
Study: 36280151
Drug: Accelerated hypofractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hypofractionated radiotherapy (1.8 Gy daily to PTV with a 0.6 Gy boost to GTV, total 45 Gy to PTV and 60 Gy to GTV in 25 fractions over 5 weeks)
Study: 36280151
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiotherapy (2 Gy daily to PTV, total 44 Gy to PTV and 60 Gy to GTV in 30 fractions over 6 weeks)
Study: 32162822
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy (PCT)